Oragenics Inc. Common Stock (OGEN)

Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Oragenics shares are trading lower by 47% during Wednesday's session. The company announced a $4.45 million public offering.

Oragenics just reported results for the second quarter of 2024.

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Oragenics just reported results for the fourth quarter of 2023.

Oragenics shares are trading lower by 21% during Tuesday's session. The company announced pricing of its public offering.

Oragenics completed a key study showing its nasal spray drug ONP-002 effectively targets brain-related nasal areas, setting the stage for Phase 2 trials in concussion treatment.

Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial.

Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant unmet medical need for concussion treatment.

Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!